Advertisement

Topics

Blood and Plasma Collection For Use in Future H1N1 (Swine Flu) Clinical Trials

2014-08-27 03:13:14 | BioPortfolio

Summary

Treatment options are limited for the new strain of the H1N1 influenza virus, which differs from the seasonal H1N1 influenza virus. This study will collect blood from people who have been exposed to the H1N1 virus or who have received the H1N1 vaccine. The blood plasma will be used in a future clinical trial to treat people hospitalized with H1N1 influenza.

Description

Swine origin influenza virus (A/H1N1), commonly referred to as "swine flu," is a new influenza virus, which differs from the seasonal H1N1 influenza virus. Most people will not have immunity to this new H1N1 virus strain. There is a concern that this virus will become resistant to oseltamivir (commonly known as Tamiflu), as resistance to this medication has been observed in people with the seasonal H1N1 influenza virus. Because of the possibility of drug resistance, additional treatment options for the H1N1 virus are needed. The purpose of this study is to collect blood from people who have been exposed to the H1N1 virus or who have received the H1N1 vaccine. The blood will then be processed into Food and Drug Administration (FDA)-licensed fresh frozen plasma (FFP). In a future clinical trial, this plasma will be used as a treatment for people hospitalized with H1N1 influenza.

This study will enroll people who have recovered from H1N1 influenza, received the H1N1 vaccine, or have both recovered from H1N1 influenza and received the H1N1 vaccine. Participants will donate blood at FDA-licensed blood donor centers up to three times during the 240-day study period.

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Conditions

Influenza A Virus, H1N1 Subtype

Location

Naval Medical Center San Diego
San Diego
California
United States
92134

Status

Recruiting

Source

National Institute of Allergy and Infectious Diseases (NIAID)

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:13:14-0400

Clinical Trials [1331 Associated Clinical Trials listed on BioPortfolio]

Clinical Trial to Compare the Immunogenicity, Safety, and Tolerability of an Adjuvanted A(H1N1) Influenza Vaccine Versus Non-Adjuvanted A(H1N1) Influenza Vaccines in Patients With HIV-1 Infection

This is a phase III, randomized, controlled, open label study with two vaccine regimens. The study will assess the relative safety and immunogenicity of vaccine regimens comparing adjuvant...

Study of Immune Responses After Vaccination Against Seasonal Influenza Virus and Against Influenza H1N1-v Pandemic Virus in a Medical Staff.

This project may help to answer several fundamental questions related to public health regarding vaccination against influenza viruses and regarding the influenza A(H1N1)v pandemy: ...

Efficacy and Safety of Vaccination Against Influenza H1N1 in Patients With Inflammatory Bowel Diseases (IBD) Treated Immunomodulators and Biologics

The spread of Influenza H1N1 has prompted the development of vaccines against this virus. IBD patients are at increased risk of developing complications of Influenza H1N1. The efficacy and...

Clinical Trial to Compare the Immunogenicity, Safety, and Tolerability of an Adjuvanted A(H1N1) Influenza Vaccine Versus Non-Adjuvanted A(H1N1) Influenza Vaccines in Patients With Invasive Solid Tumors

This is a phase III, randomized, controlled, open label study with two vaccine regimens. The study will assess the relative safety and immunogenicity of vaccine regimens comparing adjuvant...

A Pragmatic Randomized Controlled Trial of Chinese Herbal Medicine for Severe Pandemic H1N1 Influenza

The aim of this study is to evaluate the effectiveness and safety of Chinese herbal medicines for severe pandemic H1N1 influenza.

PubMed Articles [4903 Associated PubMed Articles listed on BioPortfolio]

Influence of Birth Cohort on Effectiveness of 2015-2016 Influenza Vaccine Against Medically Attended Illness Due to 2009 Pandemic Influenza A(H1N1) Virus in the United States.

The effectiveness of influenza vaccine during 2015-2016 was reduced in some age groups as compared to that in previous 2009 pandemic influenza A(H1N1) virus (A[H1N1]pdm09 virus)-predominant seasons. W...

Influenza surveillance in Western Turkey in the era of quadrivalent vaccines: A 2003-2016 retrospective analysis.

Human influenza is predominantly caused by influenza A virus (IAV) - A/H1N1 and/or A/H3N2 - and influenza B virus (IBV) - B/Victoria and/or B/Yamagata, which co-circulate each season. Influenza survei...

Aniline-based inhibitors of influenza H1N1 virus acting on hemagglutinin-mediated fusion.

Two series of easily accessible anilines were identified as inhibitors of influenza A virus subtype H1N1, and extensive chemical synthesis and analysis of the structure-activity relationship were perf...

1918 H1N1 influenza virus replicates and induces pro-inflammatory cytokine responses in extra-respiratory tissues of ferrets.

The 1918 Spanish H1N1 influenza pandemic was the most severe recorded influenza pandemic with an estimated 20-50 million deaths worldwide. Even though it is known that influenza viruses can cause extr...

Oseltamivir-Resistant Influenza A(H1N1)pdm09 virus associated with high case fatality, India 2015.

Introduction Influenza A viruses has been associated with severe global pandemics of high morbidity and mortality with devastating impact on human health and global economy. India witnessed a major ou...

Medical and Biotech [MESH] Definitions

A subtype of INFLUENZA A VIRUS comprised of the surface proteins hemagglutinin 1 and neuraminidase 1. The H1N1 subtype was responsible for the Spanish flu pandemic of 1918.

A subtype of INFLUENZA A VIRUS with the surface proteins hemagglutinin 7 and neuraminidase 9. This avian origin virus was first identified in humans in 2013.

A subtype of INFLUENZA A VIRUS that is highly virulent in poultry and wild birds, but shows varying degrees of pathogenicity in mice. The H5N8 virus subtype has a polybasic amino acid motif at the HA cleavage site which explains its pathogenicity in birds, and expresses surface proteins HEMAGGLUTININ 5 and NEURAMINIDASE 8 which are typical of Highly Pathogenic Avian Influenza viruses.

A subtype of INFLUENZA A VIRUS comprised of the surface proteins hemagglutinin 3 and neuraminidase 2. The H3N2 subtype was responsible for the Hong Kong flu pandemic of 1968.

A subtype of INFLUENZA A VIRUS comprised of the surface proteins HEMAGGLUTININ 10 and NEURAMINIDASE 8. The H10N8 subtype usually infects domestic birds (POULTRY) but there have been some human infections reported.

More From BioPortfolio on "Blood and Plasma Collection For Use in Future H1N1 (Swine Flu) Clinical Trials"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Swine Flu - H1N1 influenza - H7N9
Swine flu is the common name given to a relatively new strain of influenza (flu) that caused a flu pandemic in 2009-2010. It is also referred to as H1N1 influenza (because it is the H1N1 strain of virus). The H1N1 flu virus will be one of the main vi...

Influenza
Influenza or 'flu' is a respiratory illness associated with infection by influenza virus. Symptoms frequently include headache, fever, cough, sore throat, aching muscles and joints. There is a wide spectrum of severity of illness ranging from min...

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...


Searches Linking to this Trial